TenSixteen Bio aims to leverage its platform to address how somatic mutations that accumulate in our blood and other tissues offer new therapeutic avenues for a broad range of diseases including cancer and cardiovascular disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/28/22 | $40,000,000 |
Foresite Capital GV | undisclosed |
